Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTB003 in Thyroid Eye Disease
NCT07462130Phase 2Not yet recruiting
- Sponsor
- Nanjing Chia-Tai Tianqing Pharmaceutical
- Start
- Mar 2026
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, double-blind trial of NTB003 in thyroid eye disease (TED), sponsored by Nanjing Chia-Tai Tianqing Pharmaceutical. Primary endpoint: Proptosis Responder Rate in the study eye at 12 weeks. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
NTB003
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT07462130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07462130.